PrAg-U2

A mutated form of **anthrax protective antigen (PrAg)**, **PrAg-U2** replaces the native furin cleavage site with a **urokinase plasminogen activator (uPA)** substrate sequence. On its own, PrAg-U2 is not toxic; when combined with a recombinant effector protein such as FP59, it creates a fusion toxin system that is selectively toxic to cells with high surface uPA activity, sparing normal cells. This strategy allows for highly specific targeting of uPA-expressing cells (for example, certain tumor cells), rendering the complex a research tool for assessing uPA function in vivo and a potential template for targeted toxin therapy in cancer and vascular diseases. In preclinical models, PrAg-U2 combined with FP59 showed significant tumor reduction and high specificity, and has also been used to probe the activity of uPA inhibitors[1][3][5].

Other names

PrAg-U2PrAg-U-2PrAg-U 2